SCHEDULE: SEG Opportunity Fund Discloses 7.1% Stake in Silo Pharma

SEG Opportunity Fund, LLC has reported a 7.1% beneficial ownership stake in Silo Pharma, Inc., totaling 952,381 shares of common stock.

Summary

• SEG Opportunity Fund, LLC reported beneficial ownership of 952,381 shares of Silo Pharma, Inc. common stock.
• This represents 7.1% of Silo Pharma's outstanding common stock.
• The percentage is calculated based on 13,318,273 shares outstanding after a Registered Direct Offering of shares of Common Stock and Warrants on October 1, 2025.
• SEG Opportunity Fund, LLC holds shared voting power and shared dispositive power over all 952,381 shares.
• The acquisition was not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by an institutional investor is generally a positive signal, indicating confidence in the company's prospects without suggesting activist intentions.

Positives

• A significant institutional investor, SEG Opportunity Fund, LLC, has taken a substantial stake in Silo Pharma, Inc., indicating potential confidence in the company's future.
• The investment is stated to be passive, not intended to influence control, which can be seen as a stable, long-term holding.

Future Outlook

This filing does not contain forward-looking statements or guidance from the issuer. It is a disclosure of current ownership by a reporting person.

Management Comments

• Joseph Reda, Manager of SEG Opportunity Fund, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates an institutional investor's confidence in Silo Pharma, Inc., which is a common occurrence in the public markets as funds take positions in companies they believe have growth potential. Without more information on Silo Pharma's specific industry, detailed comparisons are difficult.

Comparison to Industry Standards

• This filing is a standard disclosure of a significant ownership stake by an institutional investor, consistent with regulatory requirements for passive investments exceeding 5%.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor could be viewed positively, potentially increasing investor confidence and liquidity.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment in Silo Pharma, Inc., which is generally a positive signal for market confidence. However, without additional financial or operational details about Silo Pharma, Inc. itself, a stronger recommendation cannot be made based solely on this beneficial ownership report. The investment suggests a belief in the company's long-term value, warranting a 'hold' for existing investors and further due diligence for potential new investors.

Keywords

Silo Pharma, SEG Opportunity Fund, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Schedule 13G, Equity Stake